- Cardiff Oncology appoints Leila Alland, MD, as Interim Chief Medical Officer.
- Company prepares to initiate registrational Phase 3 study in Q1 2027.
- Management change is interim with minimal immediate financial or clinical impact.
? Neutral AI Sentiment (+0.5 / 10)